WO2008117828A1 - 即効型核酸送達用キャリアー組成物 - Google Patents

即効型核酸送達用キャリアー組成物 Download PDF

Info

Publication number
WO2008117828A1
WO2008117828A1 PCT/JP2008/055730 JP2008055730W WO2008117828A1 WO 2008117828 A1 WO2008117828 A1 WO 2008117828A1 JP 2008055730 W JP2008055730 W JP 2008055730W WO 2008117828 A1 WO2008117828 A1 WO 2008117828A1
Authority
WO
WIPO (PCT)
Prior art keywords
nucleic acid
acid delivery
delivery carrier
prompt
carrier composition
Prior art date
Application number
PCT/JP2008/055730
Other languages
English (en)
French (fr)
Inventor
Hirofumi Takeuchi
Yasuyuki Hira
Koji Nakano
Hidekazu Toyobuku
Original Assignee
Otsuka Pharmaceutical Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to SI200831495T priority Critical patent/SI2140870T1/sl
Priority to DK08738918.5T priority patent/DK2140870T3/en
Priority to JP2009506363A priority patent/JP5349293B2/ja
Priority to AU2008230379A priority patent/AU2008230379B2/en
Priority to US12/532,949 priority patent/US9315828B2/en
Priority to UAA200910735A priority patent/UA97143C2/ru
Priority to NZ579804A priority patent/NZ579804A/en
Priority to PL08738918T priority patent/PL2140870T3/pl
Priority to RU2009139246/15A priority patent/RU2476229C2/ru
Priority to CN200880010035.6A priority patent/CN101646443B/zh
Application filed by Otsuka Pharmaceutical Co., Ltd. filed Critical Otsuka Pharmaceutical Co., Ltd.
Priority to ES08738918.5T priority patent/ES2542864T3/es
Priority to BRPI0809634-1A2A priority patent/BRPI0809634A2/pt
Priority to KR1020097021571A priority patent/KR101459391B1/ko
Priority to CA002682490A priority patent/CA2682490A1/en
Priority to EP08738918.5A priority patent/EP2140870B1/en
Priority to MX2009010336A priority patent/MX2009010336A/es
Publication of WO2008117828A1 publication Critical patent/WO2008117828A1/ja
Priority to ZA2009/06576A priority patent/ZA200906576B/en
Priority to IL201116A priority patent/IL201116A0/en
Priority to HK10104730.5A priority patent/HK1139041A1/xx
Priority to HRP20150927TT priority patent/HRP20150927T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific

Abstract

本発明の目的は、siRNA等の核酸を動物由来細胞又は動物に投与した場合に、核酸を効率的に細胞内へ送達させることができ、しかも低毒性で安全性が高い核酸送達用キャリアー、及び該キャリアーと核酸を含有する核酸送達用組成物を提供することである。(A)ジアシルホスファチジルコリン、(B)コレステロール及びその誘導体よりなる群から選択される少なくとも１種、及び(C)脂肪族第１級アミンを組み合わせて配合して核酸送達用キャリアーを調製する。また、当該核酸送達用キャリアーと核酸を混合して、核酸送達用組成物を調製する。
PCT/JP2008/055730 2007-03-26 2008-03-26 即効型核酸送達用キャリアー組成物 WO2008117828A1 (ja)

Priority Applications (20)

Application Number Priority Date Filing Date Title
ES08738918.5T ES2542864T3 (es) 2007-03-26 2008-03-26 Composición portadora de administración rápida de ácidos nucleicos
DK08738918.5T DK2140870T3 (en) 2007-03-26 2008-03-26 The carrier composition for immediate nukleinsyrefremføring
AU2008230379A AU2008230379B2 (en) 2007-03-26 2008-03-26 Prompt nucleic acid delivery carrier composition
US12/532,949 US9315828B2 (en) 2007-03-26 2008-03-26 Prompt nucleic acid delivery carrier composition
UAA200910735A UA97143C2 (ru) 2007-03-26 2008-03-26 КОМПОЗИЦИЯ НОСИТЕЛЯ ДЛЯ СВОЕВРЕМЕННОЙ ДОСТАВКИ миРНК
NZ579804A NZ579804A (en) 2007-03-26 2008-03-26 Prompt nucleic acid delivery carrier composition
PL08738918T PL2140870T3 (pl) 2007-03-26 2008-03-26 Kompozycja nośnikowa dla natychmiastowego dostarczania kwasu nukleinowego
BRPI0809634-1A2A BRPI0809634A2 (pt) 2007-03-26 2008-03-26 COMPOSIÇÃO-VEÍCULO PARA TRANSFERêNCIA RÁPIDA DE ÁCIDOS NUCLEICOS
CN200880010035.6A CN101646443B (zh) 2007-03-26 2008-03-26 速效型核酸转运用载体组合物
SI200831495T SI2140870T1 (sl) 2007-03-26 2008-03-26 Nosilni sestavek za takojšnjo dostavo nukleinske kisline
JP2009506363A JP5349293B2 (ja) 2007-03-26 2008-03-26 即効型核酸送達用キャリアー組成物
RU2009139246/15A RU2476229C2 (ru) 2007-03-26 2008-03-26 Композиция носителя для своевременной доставки нуклеиновых кислот
KR1020097021571A KR101459391B1 (ko) 2007-03-26 2008-03-26 즉효형 핵산 송달용 캐리어 조성물
CA002682490A CA2682490A1 (en) 2007-03-26 2008-03-26 Prompt nucleic acid delivery carrier composition
EP08738918.5A EP2140870B1 (en) 2007-03-26 2008-03-26 Prompt nucleic acid delivery carrier composition
MX2009010336A MX2009010336A (es) 2007-03-26 2008-03-26 Composicion de vehiculo de rapido suministro de acido nucleico.
ZA2009/06576A ZA200906576B (en) 2007-03-26 2009-09-21 Prompt nucleic acid delivery carrier composition
IL201116A IL201116A0 (en) 2007-03-26 2009-09-23 Prompt nucleic acid delivery carrier composition
HK10104730.5A HK1139041A1 (en) 2007-03-26 2010-05-14 Prompt nucleic acid delivery carrier composition
HRP20150927TT HRP20150927T1 (hr) 2007-03-26 2015-09-03 Sastav nosaäśa za brzu isporuku nukleinske kiseline

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007-079944 2007-03-26
JP2007079944 2007-03-26

Publications (1)

Publication Number Publication Date
WO2008117828A1 true WO2008117828A1 (ja) 2008-10-02

Family

ID=39788561

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/055730 WO2008117828A1 (ja) 2007-03-26 2008-03-26 即効型核酸送達用キャリアー組成物

Country Status (27)

Country Link
US (1) US9315828B2 (ja)
EP (1) EP2140870B1 (ja)
JP (1) JP5349293B2 (ja)
KR (1) KR101459391B1 (ja)
CN (1) CN101646443B (ja)
AR (1) AR065847A1 (ja)
AU (1) AU2008230379B2 (ja)
BR (1) BRPI0809634A2 (ja)
CA (1) CA2682490A1 (ja)
CO (1) CO6241127A2 (ja)
DK (1) DK2140870T3 (ja)
ES (1) ES2542864T3 (ja)
HK (1) HK1139041A1 (ja)
HR (1) HRP20150927T1 (ja)
HU (1) HUE027053T2 (ja)
IL (1) IL201116A0 (ja)
MX (1) MX2009010336A (ja)
MY (1) MY151450A (ja)
NZ (1) NZ579804A (ja)
PL (1) PL2140870T3 (ja)
PT (1) PT2140870E (ja)
RU (1) RU2476229C2 (ja)
SI (1) SI2140870T1 (ja)
TW (1) TWI428135B (ja)
UA (1) UA97143C2 (ja)
WO (1) WO2008117828A1 (ja)
ZA (1) ZA200906576B (ja)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2405001A1 (en) * 2009-03-04 2012-01-11 Takeuchi, Hirofumi Nucleic acid complex and nucleic acid-delivering composition
JP2013135623A (ja) * 2011-12-28 2013-07-11 National Cerebral & Cardiovascular Center 核酸導入剤、核酸導入方法及び細胞

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011133658A1 (en) 2010-04-22 2011-10-27 Boston Medical Center Corporation Compositions and methods for targeting and delivering therapeutics into cells
WO2012040184A2 (en) 2010-09-20 2012-03-29 Merck Sharp & Dohme Corp. Novel low molecular weight cationic lipids for oligonucleotide delivery
US10975388B2 (en) 2016-12-14 2021-04-13 Ligandal, Inc. Methods and compositions for nucleic acid and protein payload delivery

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995024201A1 (fr) * 1994-03-11 1995-09-14 Yoshitomi Pharmaceutical Industries, Ltd. Preparation de liposomes
JPH10313872A (ja) * 1997-05-21 1998-12-02 Soyaku Gijutsu Kenkyusho:Kk 抗インフルエンザウイルス剤
WO1999013816A2 (en) * 1997-09-16 1999-03-25 Nexstar Pharmaceuticals, Inc. Liposomal camptothecin formulations
JPH11292795A (ja) * 1998-04-02 1999-10-26 Yamanouchi Pharmaceut Co Ltd Ｈｉｖコファクター抑制剤
JP2002529439A (ja) 1998-11-12 2002-09-10 インビトロジェン コーポレイション トランスフェクション薬剤
WO2004017940A2 (en) * 2002-08-20 2004-03-04 Neopharm, Inc. Pharmaceutically active lipid based formulation of sn38
JP2005508394A (ja) 2001-11-06 2005-03-31 マイラス コーポレイション ｓｉＲＮＡ、両親媒性化合物及びポリカチオンを用いた組成物及び方法
WO2005102268A2 (de) * 2004-04-22 2005-11-03 Sanochemia Pharmazeutika Ag Cholinesterase-inhibitoren in liposomen sowie deren herstellung und verwendung
JP2005336081A (ja) * 2004-05-26 2005-12-08 Anges Mg Inc Ｎｒ２ｂ−ｎｍｄａ受容体の再発現抑制剤
WO2006002538A1 (en) * 2004-07-02 2006-01-12 Protiva Biotherapeutics, Inc. Immunostimulatory sirna molecules and uses therefor

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6126964A (en) * 1996-01-04 2000-10-03 Mirus Corporation Process of making a compound by forming a polymer from a template drug
US6358523B1 (en) * 1996-12-06 2002-03-19 The Regents Of The University Of California Macromolecule-lipid complexes and methods for making and regulating
US6835395B1 (en) * 1997-05-14 2004-12-28 The University Of British Columbia Composition containing small multilamellar oligodeoxynucleotide-containing lipid vesicles
US6740335B1 (en) * 1997-09-16 2004-05-25 Osi Pharmaceuticals, Inc. Liposomal camptothecin formulations
CA2421409A1 (fr) * 2000-09-08 2002-03-14 Aventis Pasteur Utilisation de lipopeptides pour l'immunotherapie des sujets vih+
US20060030578A1 (en) * 2002-08-20 2006-02-09 Neopharm, Inc. Pharmaceutically active lipid based formulation of irinotecan
AU2003288119B2 (en) * 2002-11-21 2009-08-20 Pevion Biotech Ltd. High-efficiency fusogenic vesicles, methods of producing them, and pharmaceutical compositions containing them
US20040208921A1 (en) * 2003-01-14 2004-10-21 Ho Rodney J. Y. Lipid-drug formulations and methods for targeted delivery of lipid-drug complexes to lymphoid tissues
MXPA05013239A (es) * 2003-06-27 2006-03-09 Sumitomo Chemical Co Compuestos de amida y metodos para controlar enfermedades vegetales con los mismos.
WO2005007196A2 (en) * 2003-07-16 2005-01-27 Protiva Biotherapeutics, Inc. Lipid encapsulated interfering rna
JP2007505925A (ja) * 2003-09-17 2007-03-15 レット ゼア ビー ホープ メディカル リサーチ インスティチュート 骨髄性およびリンパ様免疫細胞への薬物の送達のための標的化脂質薬物製剤
EP1759691A1 (en) 2003-11-20 2007-03-07 Delex Therapeutics Inc. Stable liposome compositions
WO2006053430A1 (en) * 2004-11-17 2006-05-26 Protiva Biotherapeutics, Inc. Sirna silencing of apolipoprotein b
CN101346468B (zh) * 2005-06-15 2016-03-30 麻省理工学院 含胺脂质和其用途
US20070160658A1 (en) * 2005-10-20 2007-07-12 The Penn State Research Foundation Delivery system for diagnostic and therapeutic agents
UA97559C2 (uk) 2007-11-08 2012-02-27 Оцука Фармасьютікал Ко., Лтд. Комплекс нуклеїнової кислоти і композиція для доставки нуклеїнової кислоти

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995024201A1 (fr) * 1994-03-11 1995-09-14 Yoshitomi Pharmaceutical Industries, Ltd. Preparation de liposomes
JPH10313872A (ja) * 1997-05-21 1998-12-02 Soyaku Gijutsu Kenkyusho:Kk 抗インフルエンザウイルス剤
WO1999013816A2 (en) * 1997-09-16 1999-03-25 Nexstar Pharmaceuticals, Inc. Liposomal camptothecin formulations
JPH11292795A (ja) * 1998-04-02 1999-10-26 Yamanouchi Pharmaceut Co Ltd Ｈｉｖコファクター抑制剤
JP2002529439A (ja) 1998-11-12 2002-09-10 インビトロジェン コーポレイション トランスフェクション薬剤
JP2005508394A (ja) 2001-11-06 2005-03-31 マイラス コーポレイション ｓｉＲＮＡ、両親媒性化合物及びポリカチオンを用いた組成物及び方法
WO2004017940A2 (en) * 2002-08-20 2004-03-04 Neopharm, Inc. Pharmaceutically active lipid based formulation of sn38
WO2005102268A2 (de) * 2004-04-22 2005-11-03 Sanochemia Pharmazeutika Ag Cholinesterase-inhibitoren in liposomen sowie deren herstellung und verwendung
JP2005336081A (ja) * 2004-05-26 2005-12-08 Anges Mg Inc Ｎｒ２ｂ−ｎｍｄａ受容体の再発現抑制剤
WO2006002538A1 (en) * 2004-07-02 2006-01-12 Protiva Biotherapeutics, Inc. Immunostimulatory sirna molecules and uses therefor

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP2140870A4

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2405001A1 (en) * 2009-03-04 2012-01-11 Takeuchi, Hirofumi Nucleic acid complex and nucleic acid-delivering composition
EP2405001A4 (en) * 2009-03-04 2013-05-22 Hirofumi Takeuchi NUCLEIC ACID COMPLEX AND NUCLEIC ACID DELIVERING COMPOSITION
US9090912B1 (en) 2009-03-04 2015-07-28 Hirofumi Takeuchi Nucleic acid complex and nucleic acid-delivering composition
JP5808246B2 (ja) * 2009-03-04 2015-11-10 大塚製薬株式会社 核酸複合体、及び核酸送達用組成物
JP2013135623A (ja) * 2011-12-28 2013-07-11 National Cerebral & Cardiovascular Center 核酸導入剤、核酸導入方法及び細胞

Also Published As

Publication number Publication date
CN101646443A (zh) 2010-02-10
ES2542864T3 (es) 2015-08-12
MX2009010336A (es) 2009-10-16
IL201116A0 (en) 2010-05-17
NZ579804A (en) 2012-05-25
HRP20150927T1 (hr) 2015-10-09
BRPI0809634A2 (pt) 2014-09-23
CA2682490A1 (en) 2008-10-02
CO6241127A2 (es) 2011-01-20
KR101459391B1 (ko) 2014-11-07
KR20090130056A (ko) 2009-12-17
RU2009139246A (ru) 2011-05-10
EP2140870A4 (en) 2011-09-07
SI2140870T1 (sl) 2015-10-30
HK1139041A1 (en) 2010-09-10
PT2140870E (pt) 2015-09-15
ZA200906576B (en) 2010-11-24
EP2140870B1 (en) 2015-06-24
AR065847A1 (es) 2009-07-08
HUE027053T2 (en) 2016-08-29
US20100063131A1 (en) 2010-03-11
MY151450A (en) 2014-05-30
DK2140870T3 (en) 2015-07-20
TW200902035A (en) 2009-01-16
TWI428135B (zh) 2014-03-01
AU2008230379A1 (en) 2008-10-02
RU2476229C2 (ru) 2013-02-27
US9315828B2 (en) 2016-04-19
CN101646443B (zh) 2015-01-14
JPWO2008117828A1 (ja) 2010-07-15
PL2140870T3 (pl) 2015-11-30
AU2008230379B2 (en) 2012-12-06
EP2140870A1 (en) 2010-01-06
UA97143C2 (ru) 2012-01-10
JP5349293B2 (ja) 2013-11-20

Similar Documents

Publication Publication Date Title
EP3418386A3 (en) Compositions and methods for inhibiting gene expression of hepatitis b virus
WO2010099383A3 (en) Compositions and methods for ex vivo hepatic nucleic acid delivery
WO2012024526A3 (en) Conjugates, particles, compositions, and related methods
WO2008011636A3 (en) Targeted gene delivery for dendritic cell vaccination
WO2012033794A3 (en) Aad-12 event 1606 and related transgenic soybean lines
WO2011008495A3 (en) Arginase formulations and methods
WO2009065561A3 (en) System for delivery into a xcr1 positive cell and uses thereof
WO2007139723A8 (en) Chemicallymodified oligonucleotide primers for nucleic acid amplification
WO2008093195A3 (en) Chitosan-based colloidal particles for rna delivery
WO2009014887A3 (en) Stabilized immune modulatory rna (simra) compounds
WO2007118245A8 (en) Methods and compositions related to adenoassociated virus-phage particles
WO2007117686A3 (en) Stabilized immune modulatory rna (simra) compounds for tlr7 and tlr8
MX2014004618A (es) Formulaciones antimicrobianas con acido pelargonico.
WO2008117828A1 (ja) 即効型核酸送達用キャリアー組成物
WO2009074970A3 (en) Means for delivery of nucleic acids active for gene silencing using synthetic polymers
EP2692723A8 (en) Aryloxy dihalopropenyl ether compound and use thereof
WO2005086896A3 (en) Delivery vectors for short interfering rna, micro-rna and antisense rna
WO2009006446A3 (en) Methods for cloning small rna species
WO2011071535A3 (en) Compositions and methods for inhibiting human host cell factors required for influenza virus replication
WO2009061003A3 (en) Nucleic acid complex and nucleic acid delivery composition
WO2008087774A1 (ja) 抗酸化剤
WO2011054939A3 (en) Compositions and methods for inhibiting expression of kif10 genes
EP1908825A4 (en) AGAINST PAP2A-TUNNELED ANTIBODY AND ITS USE FOR DIAGNOSTIC AND THERAPEUTIC PURPOSES
WO2012003030A3 (en) Methods of identifying & using anti-viral compounds
EP2851426A3 (en) Compositions and methods for inhibiting expression of RRM2 genes

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200880010035.6

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08738918

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 12009501758

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: 2008230379

Country of ref document: AU

Ref document number: 579804

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 201116

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 12532949

Country of ref document: US

Ref document number: 2009091400

Country of ref document: EG

ENP Entry into the national phase

Ref document number: 2682490

Country of ref document: CA

Ref document number: 2009506363

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 6156/DELNP/2009

Country of ref document: IN

Ref document number: MX/A/2009/010336

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: PI20093905

Country of ref document: MY

WWE Wipo information: entry into national phase

Ref document number: 2008738918

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2008230379

Country of ref document: AU

Date of ref document: 20080326

Kind code of ref document: A

Ref document number: 20097021571

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2009139246

Country of ref document: RU

Ref document number: 09120191

Country of ref document: CO

ENP Entry into the national phase

Ref document number: PI0809634

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20090925